Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 10/20 | 0.46 |
| ▸ | RXRB | P28702 | 6/20 | 0.43 |
| ▸ | RARB | P10826 | 4/20 | 0.43 |
| ▸ | RARG | P13631 | 4/20 | 0.43 |
| ▸ | RXRG | P48443 | 4/20 | 0.43 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.39 |
| ▸ | CYP26B1 | Q9NR63 | 2/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | RARA | P10276 | 3/20 | 0.35 |
| ▸ | TYR | P14679 | 1/20 | 0.33 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11122818 | 0.82 | RARB (0.41) | RXRARXRBRARBRARGRXRG | |
| SCHEMBL22302453 | 0.76 | TYR (0.43) | HSP90AA1HSP90AB1TYR | |
| SCHEMBL4666462 | 0.76 | RARG (0.51) | RXRARXRBRARBRARGRXRG | |
| SCHEMBL8807547 | 0.74 | RXRA (0.44) | RXRARXRBRARBRARGRXRG | |
| SCHEMBL4666464 | 0.74 | PRKDC (0.44) | RXRARXRBRARBRARGRXRG | |
| SCHEMBL4666402 | 0.74 | RARG (0.43) | RXRARXRBRARBRARGRXRG | |
| SCHEMBL7223563 | 0.74 | RXRA (0.43) | RXRARXRBRARBRARGRXRG | |
| SCHEMBL29818615 | 0.74 | TYR (0.42) | HSP90AA1HSP90AB1TYR | |
| SCHEMBL5947942 | 0.73 | RXRA (0.44) | RXRARXRBRARBRARGRXRG | |
| SCHEMBL22838113 | 0.72 | RXRA (0.47) | RXRARXRBRARBRARGRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6624188-B1 | Administered to treat or prevent one or more of the diseases and conditions selected from the group consisting of dermatoses, atherosclerosis and restenosis resulting from neointimal hyperproliferation, non-malignant and | ALLERGAN, INC. | 2003-09-23 | — | — | US | disclosed |
| US-5475113-A | Treatment of skin disorders, skin cancer | ALLERGAN, INC. (US) | 1995-12-12 | — | — | US | disclosed |
| US-5324840-A | Skin disorders | ALLERGAN, INC. (US) | 1994-06-28 | — | — | US | disclosed |